Cargando…

Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey

Background: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in...

Descripción completa

Detalles Bibliográficos
Autores principales: Çiçek, Davran, Pekdemir, Hasan, Haberal, Cevahir, Kalay, Nihat, Binici, Süleyman, Altay, Hakan, Müderrisoğlu, Haldun
Formato: Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020394/
https://www.ncbi.nlm.nih.gov/pubmed/21234271
_version_ 1782196302640054272
author Çiçek, Davran
Pekdemir, Hasan
Haberal, Cevahir
Kalay, Nihat
Binici, Süleyman
Altay, Hakan
Müderrisoğlu, Haldun
author_facet Çiçek, Davran
Pekdemir, Hasan
Haberal, Cevahir
Kalay, Nihat
Binici, Süleyman
Altay, Hakan
Müderrisoğlu, Haldun
author_sort Çiçek, Davran
collection PubMed
description Background: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes of these two drug-eluting stents in the real-world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the zotarolimus- or the paclitaxel-eluting stent. The follow-up period was approximately two years. The primary end-point was major cardiac events, and the secondary end-point was definite stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 217 patients were treated with either the zotarolimus-eluting stent (n = 116) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up the paclitaxel-eluting stent group showed significantly higher non-Q wave myocardial infarction (2.6% vs 5.9%, p: 0.02), Q wave myocardial infarction (1.7% vs 5.9%, p: 0.049), coronary artery binding graft surgery (2.6% vs 6.9%, p: 0.002), and late stent thrombosis (1.7% vs 3.9%, p: 0.046). Conclusions: Zotarolimus-eluting stents demonstrated better clinical outcomes than Paclitaxel-eluting stents in a daily routine practice of coronary intervention in an unselected Turkish population.
format Text
id pubmed-3020394
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-30203942011-01-13 Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey Çiçek, Davran Pekdemir, Hasan Haberal, Cevahir Kalay, Nihat Binici, Süleyman Altay, Hakan Müderrisoğlu, Haldun Int J Med Sci Research Paper Background: Our purpose was to investigate the clinical outcomes of Zotarolimus- and Paclitaxel-eluting stents in Turkish patients with coronary artery disease (CAD). In general, the outcome of drug-eluting stent (DES) placement has a proven efficacy in randomized trials. However, the difference in efficacy between the Zotarolimus and Paclitaxel-eluting stents in unselected Turkish patients is controversial. Therefore, we investigated the clinical outcomes of these two drug-eluting stents in the real-world. Methods: We created a registry and prospectively analyzed data on a consecutive series of all patients who presented to our institution with symptomatic coronary artery disease between February 2005 and March 2007 and who were treated with the zotarolimus- or the paclitaxel-eluting stent. The follow-up period was approximately two years. The primary end-point was major cardiac events, and the secondary end-point was definite stent thrombosis. Informed consent was obtained from all subjects, and the study protocol was approved by the local ethical committee. Results: In total, 217 patients were treated with either the zotarolimus-eluting stent (n = 116) or the paclitaxel-eluting stent (n = 101). The lesions in the 2 arms of the study were treated similarly by conventional technique. At 24-month follow-up the paclitaxel-eluting stent group showed significantly higher non-Q wave myocardial infarction (2.6% vs 5.9%, p: 0.02), Q wave myocardial infarction (1.7% vs 5.9%, p: 0.049), coronary artery binding graft surgery (2.6% vs 6.9%, p: 0.002), and late stent thrombosis (1.7% vs 3.9%, p: 0.046). Conclusions: Zotarolimus-eluting stents demonstrated better clinical outcomes than Paclitaxel-eluting stents in a daily routine practice of coronary intervention in an unselected Turkish population. Ivyspring International Publisher 2011-01-08 /pmc/articles/PMC3020394/ /pubmed/21234271 Text en © Ivyspring International Publisher. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.
spellingShingle Research Paper
Çiçek, Davran
Pekdemir, Hasan
Haberal, Cevahir
Kalay, Nihat
Binici, Süleyman
Altay, Hakan
Müderrisoğlu, Haldun
Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
title Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
title_full Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
title_fullStr Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
title_full_unstemmed Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
title_short Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turkey
title_sort two-year outcome of turkish patients treated with zotarolimus versus paclitaxel eluting stents in an unselected population with coronary artery disease in the real world: a prospective non-randomized registry in southern turkey
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020394/
https://www.ncbi.nlm.nih.gov/pubmed/21234271
work_keys_str_mv AT cicekdavran twoyearoutcomeofturkishpatientstreatedwithzotarolimusversuspaclitaxelelutingstentsinanunselectedpopulationwithcoronaryarterydiseaseintherealworldaprospectivenonrandomizedregistryinsouthernturkey
AT pekdemirhasan twoyearoutcomeofturkishpatientstreatedwithzotarolimusversuspaclitaxelelutingstentsinanunselectedpopulationwithcoronaryarterydiseaseintherealworldaprospectivenonrandomizedregistryinsouthernturkey
AT haberalcevahir twoyearoutcomeofturkishpatientstreatedwithzotarolimusversuspaclitaxelelutingstentsinanunselectedpopulationwithcoronaryarterydiseaseintherealworldaprospectivenonrandomizedregistryinsouthernturkey
AT kalaynihat twoyearoutcomeofturkishpatientstreatedwithzotarolimusversuspaclitaxelelutingstentsinanunselectedpopulationwithcoronaryarterydiseaseintherealworldaprospectivenonrandomizedregistryinsouthernturkey
AT binicisuleyman twoyearoutcomeofturkishpatientstreatedwithzotarolimusversuspaclitaxelelutingstentsinanunselectedpopulationwithcoronaryarterydiseaseintherealworldaprospectivenonrandomizedregistryinsouthernturkey
AT altayhakan twoyearoutcomeofturkishpatientstreatedwithzotarolimusversuspaclitaxelelutingstentsinanunselectedpopulationwithcoronaryarterydiseaseintherealworldaprospectivenonrandomizedregistryinsouthernturkey
AT muderrisogluhaldun twoyearoutcomeofturkishpatientstreatedwithzotarolimusversuspaclitaxelelutingstentsinanunselectedpopulationwithcoronaryarterydiseaseintherealworldaprospectivenonrandomizedregistryinsouthernturkey